Amneal Pharmaceuticals (AMRX) is recalling three lots of Sulfamethoxazole/Trimethoprim tablets 400mg/80mg as the tablets may exhibit black spots on the tablet surface due to microbial contamination. The observance of black spots was reported in a product quality complaint, the FDA said on its website. The product is indicated for the treatment of Urinary tract infections.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals announces FDA approved Brekiya injection
- Amneal Pharmaceuticals Approves Key Proposals at Annual Meeting
- Amneal Pharmaceuticals, Apiject announce strategic collaboration
- Amneal Pharmaceuticals Reports Strong Q1 2025 Results
- Amneal Pharma’s Earnings Call Highlights Strong Growth
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue